Interferon alpha-2b

Drug Profile

Interferon alpha-2b

Alternative Names: Intron A; SCH 30500; Viraferon; Virtron; YM 14090

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Merck & Co
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Follicular lymphoma; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Human papillomavirus infections; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top